Purpose: Aggrecanase cleavage at the 392Glu-393Ala bond in the interglobular domain of aggrecan, releasing N-terminal 393ARGS fragments into synovial fluid (SF), is an early key event in arthritis and joint injuries. We have shown that SF-ARGS is associated with radiographic progression of knee osteoarthritis (OA) as well as with progression of self-reported pain after meniscectomy. Our objective was to validate a modified ligand-binding assay for the detection of aggrecanase generated aggrecan fragments with the ARGS neoepitope in SF, blood and urine, and to verify the identity of aggrecan fragments found in blood. Methods: A sandwich enzyme-linked immunosorbent assay (ELISA) on the Meso Scale Discovery (MSD) platform for detection of ARGSaggrecan was validated, using a standard made by ADAMTS-4-digestion of recombinant human aggrecan (1220-PG, R&D Systems), an antiaggrecan antibody (AHP0022, Invitrogen) for capture, and a monoclonal anti-ARGS (OA-1, GlaxoSmithKline) for detection. We analysed recovery to dilution and spiking of equimolar concentrations of standard in SF and serum samples. Matched samples of SF, serum, plasma, and urine were obtained from 36 subjects at different time points 0 to 5 years after an anterior cruciate ligament (ACL) tear, and analysed for ARGSaggrecan content. Aggrecan was purified by caesium chloride density gradient centrifugation from serum and plasma pools and analysed by Western blot using the anti-ARGS antibody. We used Spearman's rank order correlation (rS) for assessment of correlation, based on Shapiro-Wilk test indicating skewed distributions of a majority of the variables. Results: The limits of quantification for the ARGS-aggrecan assay was between 0.2 and 0.025 pmol ARGS/ml. Inside these limits recovery to dilution was, mean (range) 100% (83-117%), and to spiking 89% (77-110%). The sensitivity of the assay was improved 2-fold compared to when using a standard purified from human donors. The ARGS concentrations were highest in SF (mean, range; 3.02, 0.36 -30.22 pmol/ ml), 20 times lower in the blood samples (0.14, 0.055 -0.28 pmol/ml serum and 0.13, 0.053 -0.28 pmol/ml plasma), and 80 times lower in urine (0.036, <0.025 -0.087 pmol/ml). Serum-ARGS and plasma-ARGS concentrations were similar, and correlated (Figure 1: rS ¼ 0.773) . SF concentrations correlated with serum and plasma concentrations (Figure 1 : rS ¼ 0.420 and 0.386, respectively). In purified serum and plasma samples, we identified 129-138 kDa aggrecan fragments containing the ARGS neoepitope.
Purpose: The synovial membrane is an important source for biomarker discovery of many rheumatic pathologies. The heterogeneity of osteoarthritis (OA) affected tissues and the spatial distribution of proteins in the human synovial membrane is poorly studied. The specific protein and peptide profiles in different areas of the synovial tissue can reveal information about the underlying pathways that play a role in the OA pathology. The distribution of these specific protein/peptide profiles can be used for tissue/patient classification. Matrix assisted laser desorption ionization mass spectrometric imaging (MALDI-MSI) is a novel technique that can be employed to reveal the molecular signature of a region or area of interest in a biological tissue. In this work, we have studied the peptide profiles and their distributions in human normal and OA synovial membranes. We have described specific OA biomarkers commonly found in cartilage and synovial tissues by MALDI-MSI. Note: the first two authors contributed equally to this work. Figure 1 . A rug-plot of bivariate scatters of ARGS-aggrecan concentrations in SF, serum, plasma and urine from 36 subjects at different times over 5 years after ACL injury. Concentrations in urine are given corrected for urinary creatinine. Filled circles are concentrations measured within the detection limits of the ARGS-aggrecan assay. Open circles are urinary ARGS concentration below the assay Lower Limit Of Quantification (LLOQ; 0.025 pmol/ml) that were imputed to half the LLOQ value. Linear regression lines (solid) with 95% confidence intervals (long dashed) are indicted in each scatter plot. In the rug-plot, each bivariate scatter plot shares information of one variate with the adjacent plot, illustrated by interconnecting rug fringes showing the marginal distribution of the shared variate. Horizontal and vertical lines (short dashed) interconnect ARGS concentrations in different bivariate combinations of fluids in one subject. All scales are logarithmic and reflect the range of ARGS concentrations in each fluid.
Methods: Human normal/OA cartilage and normal/OA synovial membranes were sectioned in triplicate in 10 mm thick sections and subsequently washed and digested. Microspots of trypsin were deposited by means of an automatic chemical inkjet printer with high positional accuracy. Alpha-Cyano-4-hydroxycinnamic acid matrix (HCCA) was deposited by a vibrational sprayer system. A Synapt HDMS MALDI-Q-TOF instrument was used to perform the imaging-MS and MS/MS experiments with a spatial raster size of 150 mm. Principal Component Analysis (PCA) and discriminant analysis (DA) were used to build regional molecualr classifiers. A Mascot query was performed after MS/MS experiments for protein identification. The location of tryptic peptides was visualized with Biomap. Hematoxylin-eosin staining and immunohistochemistry studies validated and complemented the spatial information. Results: We have studied the peptide distribution in normal and OA human synovial tissues by MALDI-MSI. By means of PCA and DA we distinguished OA and normal tissues based on their tryptic peptide profiles. Tryptic peptides from proteins such as hemoglobin subunit alpha 2 (m/z 1529.8), hemoglobin subunit beta (m/z 952.5, m/z 1126.6, m/z 1274.7, m/z 1314.7, m/z 1720.0), actin aortic smooth muscle (m/z 1790.9), biglycan (m/z 1312.8) and fibronectin (m/z 1349.7) have been identified, for the first time to our knowledge, directly from synovial membrane biopsies. We have determined the localization of OA related markers such as the heme group, hemoglobin and fibronectin, all of them co-localized to inflamed areas. Biomap software revealed that the average intensity for group heme was higher in OA compared to normal synovial membrane (0,011AE0,003 vs. 0,091AE0,029; p<0.05). Fibronectin immunohistochemistry provided complementary validation of the results obtained by MALDI-MSI. On the other hand, phosphocoline (m/z 184) was assigned as a marker of OA tissues but localized in areas of low inflammation. Cluster analyses revealed that peaks assigned to diacylglycerols and actin were molecular signatures specific to normal tissues. Finally, we studied common OA peptides analyzing human synovial and cartilage tissue sections. We have observed that fibronectin and actin related peptides clearly distinguished the diseased from the normal tissues. Pathway analyses revealed that fibronectin, hemoglobin and other OA related proteins interacted with integrin proteins suggesting that this family of proteins has an important role in the process of cartilage degradation and synovial inflammation. Conclusions: We have classified normal and OA human synovial membranes by MALDI-MSI. Peptides exclusively located in areas of high inflammation were identified revealing disease specific profiles that contribute to the understanding of OA affected tissues at the molecular level. Purpose: Recent investigations have argued that there is a close relationship between altered lipid metabolism and Osteoarthritis (OA) disease. Mesenchymal stem cells (MSC) are an interesting alternative for cell-based therapy of cartilage defects due to their capacity to differentiate towards chondrocytes in a process called chondrogenesis. The knowledge of the lipid distribution and modulation during this process could be used to improve the MSC-based cartilage therapy by the discovery of new chondrogenic markers. In this study, we have used matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) for the characterization of lipids in 3D MSC cultures (micromasses) at different time points of chondrogenesis. Methods: MSC micromasses obtained from the bone marrow of 3 OA donors were collected at day 2 and 14 of chondrogenesis and studied in duplicate. Samples were cut in sections of 10 mm thickness and dried in a vacuum desiccator for 20 min to prevent the molecular delocalization. Two matrix solutions were prepared (Alpha-cyano-4-hydroxycinnamic acid at 10 mg/ml in 70:30 methanol:trifluoroacetic acid 0.2%; 9-Aminoacridine at 10 mg/ml in 70:30 ethanol:water) and applied on the surface of the tissue slides using a vibrational sprayer (ImagePrep, Bruker, Germany). MALDI-MSI was performed using a MALDI-Q-TOF instrument (Synapt HDMS, Waters, UK) equipped with a 200-Hz Nd:YAG laser. Data were acquired in the mass/charge (m/z) range of 100-1000 and at a raster size of 100 mm (positive and negative Vreflectron mode). Ion images were generated with Biomap 3.7.5.5 software. Principal component analysis (PCA) and discriminant analysis (DA) were used to look for the masses with the highest differences between all samples studied. Finally, tandem mass spectrometry (MS/ MS) was carried out to identify these masses. Lipid assignments were performed according to literature and LIPID MAPS Structure Database (LMSD). Results: MALDI-MSI revealed a differential lipid profile between the two time points (2 and 14 days). Firstly, we analyzed the lipid composition in the positive mode. The analysis of 683 spectra by statistical methods such as PCA and DA showed a higher lipid content at day 2 of chondrogenesis. According to Lipidmaps database and MS/MS fragmentation, these peaks are attributed to phosphocholine (m/z 184) and several phosphatidylcholines (PC) (m/z 739.5, m/z 798.5 and m/z 826.6) ( Table 1) . Other differentially expressed peaks could be assigned to sphingomyelines (SM) (m/z 725.5, m/z 741.5, m/z 767.5 and m/z 826.6). Only m/z 729.5, m/z 756.5 and m/z 790.5 were increased at day 14, corresponding to SM and two PCs, respectively. For the negative mode 745 spectra were used. The first discriminant function revealed a high presence of phosphatidylinositols (PI) (m/z 885.6) and phosphatidyletanolamines (PE) such as m/z 750.5 specifically at day 14. Biomap software confirmed the results obtained by PCA and DA (Figure 1) . Conclusions: These data demonstrate that MALDI-MSI can be used for the identification of putative chondrogenic markers. We have observed that the lipid metabolism is involved in the chondrogenic process. Phosphatidyletanolamine and phosphatidylinositol pathways are increased in chondrocyte-differentiated MSC, whereas phosphocholine-related lipids could be markers of the undifferentiated stage.
